WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic disc… Read more
WuXi Biologics (WXIBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.037x
Based on the latest financial reports, WuXi Biologics (WXIBF) has a cash flow conversion efficiency ratio of 0.037x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.81 Billion) by net assets ($49.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
WuXi Biologics - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how WuXi Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
WuXi Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of WuXi Biologics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Valley National Bancorp 8.250% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C
PINK:VLYPN
|
0.001x |
|
Thomson Reuters Corporation Common Shares
NASDAQ:TRI
|
0.064x |
|
Yankuang Energy Group Co Ltd
SHG:600188
|
0.055x |
|
Jones Lang LaSalle Incorporated
NYSE:JLL
|
0.085x |
|
Somnigroup International Inc.
NYSE:SGI
|
0.136x |
|
Clorox Co.
LSE:0I0J
|
8.886x |
|
Logitech International SA
NASDAQ:LOGI
|
0.206x |
|
Coal India Limited
NSE:COALINDIA
|
0.083x |
Annual Cash Flow Conversion Efficiency for WuXi Biologics (2014–2024)
The table below shows the annual cash flow conversion efficiency of WuXi Biologics from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $45.48 Billion | $5.22 Billion | 0.115x | +8.19% |
| 2023-12-31 | $44.02 Billion | $4.67 Billion | 0.106x | -30.71% |
| 2022-12-31 | $36.21 Billion | $5.54 Billion | 0.153x | +45.87% |
| 2021-12-31 | $32.71 Billion | $3.43 Billion | 0.105x | +16.55% |
| 2020-12-31 | $20.90 Billion | $1.88 Billion | 0.090x | -3.91% |
| 2019-12-31 | $12.90 Billion | $1.21 Billion | 0.094x | -1.67% |
| 2018-12-31 | $7.99 Billion | $761.61 Million | 0.095x | +6.42% |
| 2017-12-31 | $4.02 Billion | $360.28 Million | 0.090x | -70.44% |
| 2016-12-31 | $270.47 Million | $81.92 Million | 0.303x | -58.73% |
| 2015-12-31 | $146.00 Million | $107.15 Million | 0.734x | +1168.94% |
| 2014-12-31 | $371.83 Million | $21.50 Million | 0.058x | -- |